AU2006299428B2 - Pyrimidine amide compounds as PGDS inhibitors - Google Patents

Pyrimidine amide compounds as PGDS inhibitors Download PDF

Info

Publication number
AU2006299428B2
AU2006299428B2 AU2006299428A AU2006299428A AU2006299428B2 AU 2006299428 B2 AU2006299428 B2 AU 2006299428B2 AU 2006299428 A AU2006299428 A AU 2006299428A AU 2006299428 A AU2006299428 A AU 2006299428A AU 2006299428 B2 AU2006299428 B2 AU 2006299428B2
Authority
AU
Australia
Prior art keywords
phenyl
pyrimidine
carboxylic acid
fluoro
benzylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006299428A
Other languages
English (en)
Other versions
AU2006299428A1 (en
Inventor
Suzanne C. Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventisub LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventisub LLC filed Critical Aventisub LLC
Publication of AU2006299428A1 publication Critical patent/AU2006299428A1/en
Application granted granted Critical
Publication of AU2006299428B2 publication Critical patent/AU2006299428B2/en
Assigned to AVENTISUB LLC reassignment AVENTISUB LLC Request to Amend Deed and Register Assignors: AVENTIS PHARMACEUTICALS INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006299428A 2005-10-04 2006-10-04 Pyrimidine amide compounds as PGDS inhibitors Ceased AU2006299428B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04
US60/723,570 2005-10-04
PCT/US2006/038841 WO2007041634A1 (en) 2005-10-04 2006-10-04 Pyrimidine amide compounds as pgds inhibitors

Publications (2)

Publication Number Publication Date
AU2006299428A1 AU2006299428A1 (en) 2007-04-12
AU2006299428B2 true AU2006299428B2 (en) 2012-04-26

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006299428A Ceased AU2006299428B2 (en) 2005-10-04 2006-10-04 Pyrimidine amide compounds as PGDS inhibitors

Country Status (27)

Country Link
US (1) US8202863B2 (enExample)
EP (1) EP1937652B1 (enExample)
JP (1) JP5452925B2 (enExample)
KR (1) KR101457966B1 (enExample)
CN (2) CN101538246B (enExample)
AR (1) AR056871A1 (enExample)
AU (1) AU2006299428B2 (enExample)
BR (1) BRPI0616815A2 (enExample)
CA (1) CA2624749C (enExample)
CR (1) CR9832A (enExample)
DO (1) DOP2006000210A (enExample)
EC (1) ECSP088335A (enExample)
ES (1) ES2514471T3 (enExample)
IL (1) IL190411A (enExample)
MA (1) MA29925B1 (enExample)
MY (1) MY151172A (enExample)
NO (1) NO20082000L (enExample)
NZ (1) NZ567208A (enExample)
PE (2) PE20070589A1 (enExample)
RU (1) RU2420519C2 (enExample)
SG (1) SG166121A1 (enExample)
TN (1) TNSN08104A1 (enExample)
TW (1) TWI415839B (enExample)
UA (1) UA93213C2 (enExample)
UY (1) UY29840A1 (enExample)
WO (1) WO2007041634A1 (enExample)
ZA (1) ZA200802222B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290465A1 (en) * 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CA2679198C (en) 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8222243B2 (en) 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
EP2212290B1 (en) 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JP2011503072A (ja) * 2007-11-13 2011-01-27 レノビス， インコーポレイテッド イオンチャネルのリガンドとしてのアミド誘導体ならびにそれを使用する薬学的組成物および方法
JP5537159B2 (ja) * 2008-02-06 2014-07-02 Ｍｓｄ株式会社 ３位置換スルホニルピペリジン誘導体
AU2009246446B2 (en) * 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
MY154000A (en) 2008-09-22 2015-04-30 Cayman Chem Co Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
CN102341385B (zh) 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
CA2776242C (en) * 2009-10-08 2014-09-02 Sanofi Phenyloxadiazole derivatives as pgds inhibitors
JP5677325B2 (ja) * 2010-01-22 2015-02-25 大鵬薬品工業株式会社 Ｐｇｄｓ阻害作用を有するピペラジン化合物
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
EP2615084B1 (en) 2010-09-07 2016-01-06 Taiho Pharmaceutical Co., Ltd. Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
JP2015506360A (ja) * 2012-01-06 2015-03-02 ユニバーシティ・オブ・サウス・フロリダ 組成物、使用方法および処置方法
MY182403A (en) * 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
EP3429588B1 (en) * 2016-03-14 2024-09-18 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US11149035B2 (en) 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
WO2019084529A1 (en) 2017-10-29 2019-05-02 China Medical University ADAM9 INHIBITORS AND USES THEREOF
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
AU2018413791B2 (en) * 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
BR112021008976A2 (pt) 2018-11-08 2021-08-03 Glaxosmithkline Intellectual Property Development Limited compostos químicos
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
JP7734129B2 (ja) 2020-06-19 2025-09-04 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
AU2022394333A1 (en) * 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds
EP4488271A4 (en) * 2022-02-28 2026-03-04 Japan Tobacco Inc INDAZOLE COMPOUND AND ITS PHARMACEUTICAL USE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
US20050165028A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
EP1553089B1 (en) * 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021577A2 (en) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
WO2004072069A1 (en) * 2003-02-14 2004-08-26 Glaxo Group Limited Carboxamide derivatives
WO2005032493A2 (en) * 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
US20050165028A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAPLUS Database, Accession No: 1963:20724 *

Also Published As

Publication number Publication date
NO20082000L (no) 2008-06-09
PE20110118A1 (es) 2011-03-08
UY29840A1 (es) 2007-05-31
MA29925B1 (fr) 2008-11-03
KR101457966B1 (ko) 2014-11-04
CN101282943A (zh) 2008-10-08
CR9832A (es) 2008-06-18
US20080227782A1 (en) 2008-09-18
US8202863B2 (en) 2012-06-19
TW200812977A (en) 2008-03-16
AR056871A1 (es) 2007-10-31
EP1937652B1 (en) 2014-07-30
ZA200802222B (en) 2009-09-30
ES2514471T3 (es) 2014-10-28
IL190411A (en) 2013-09-30
DOP2006000210A (es) 2007-06-15
BRPI0616815A2 (pt) 2011-07-05
EP1937652A1 (en) 2008-07-02
AU2006299428A1 (en) 2007-04-12
IL190411A0 (en) 2008-11-03
CA2624749C (en) 2011-08-16
UA93213C2 (en) 2011-01-25
CN101538246B (zh) 2014-07-16
CN101538246A (zh) 2009-09-23
TNSN08104A1 (en) 2009-07-14
NZ567208A (en) 2011-03-31
CA2624749A1 (en) 2007-04-12
PE20070589A1 (es) 2007-06-22
TWI415839B (zh) 2013-11-21
JP2009510170A (ja) 2009-03-12
WO2007041634A1 (en) 2007-04-12
SG166121A1 (en) 2010-11-29
KR20080050611A (ko) 2008-06-09
ECSP088335A (es) 2008-05-30
MY151172A (en) 2014-04-30
JP5452925B2 (ja) 2014-03-26
RU2420519C2 (ru) 2011-06-10
RU2008117170A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
CA2624749C (en) Pyrimidine amide compounds as pgds inhibitors
CA2682629C (en) Pyrimidine hydrazide compounds as pgds inhibitors
RU2417990C2 (ru) 2,6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2
CA2776242C (en) Phenyloxadiazole derivatives as pgds inhibitors
CA3024113A1 (en) Heterocyclic compounds as kinase inhibitors
CN102395584A (zh) 用于代谢疾病治疗的化合物
HK1136162A (en) Pyrimidine amide compounds as pgds inhibitors
WO2025117677A1 (en) Heterocyclic compounds useful as kcnt1 inhibitors
HK1173441B (en) Phenyloxadiazole derivatives as pgds inhibitors
HK1139413A (en) Pyrimidine hydrazide compounds as pgds inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired